JERUSALEM--(BUSINESS WIRE)--Oramed Pharmaceuticals, Inc. (OTCBB: ORMP – http://www.oramed.com), a developer of oral delivery systems, has begun Phase 1B clinical trials for its oral insulin capsule. This Phase 1B trial is focused on finding the optimal dosage for the formulation of Oramed’s proprietary oral insulin delivery technology. The study utilizes healthy human volunteers in order to determine the final formulation of the oral insulin product. This trial is a continuation of Oramed’s successfully completed Phase 1A trials, which were conducted on healthy volunteers.